Experimental CAR t therapy takes on Hard-to-Treat myeloma
NCT ID NCT05020444
First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This early-phase trial is testing a new type of CAR T cell therapy called TriPRIL for people with multiple myeloma that has returned or stopped responding to standard treatments. The therapy involves collecting a patient's own immune cells, modifying them to better attack cancer, and infusing them back after a short course of chemotherapy. The main goal is to check safety and side effects in 18 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TriPRIL CAR T cells (a type of immune cell therapy) given with chemotherapy drugs fludarabine and cyclophosphamide
- What this could lead to
- If it works, this could point toward a new treatment option for people with multiple myeloma that has come back or not responded to other therapies.
- What could go wrong
- This is a very early phase 1 trial with only 18 participants, so it is primarily checking safety, not effectiveness. The treatment may cause serious side effects, and it is too soon to know if it will work.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Engineered donor cells could outsmart relapsed myeloma
- Talking about the end: could guided conversations reduce futile cancer treatments?